Aduro starts Phase II gastric study of CRS-207

Aduro Biotech Inc. (NASDAQ:ADRO) began an open-label, U.S. Phase II trial to evaluate CRS-207 (ANZ-207) plus Keytruda pembrolizumab from Merck & Co. Inc. (NYSE:MRK) in about 70 patients with gastric, gastroesophageal junction or esophageal adenocarcinoma who have received 2 prior systemic chemotherapy treatment regimens for advanced disease.

Patients will receive Keytruda plus IV CRS-207 at a starting dose of 1x10⁹ colony-forming units (CFUs) on day 1or 2 of each 3-week cycle. After 4 cycles, patients will receive CRS-207 once every 6 weeks...